$OCGN
Ocugen, Inc. Stock $ocgn

$ocgn Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000119312517338756 Filed on November 09, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.670M	$2.230M	$1.770M
YoY Change	11.72%	25.99%	-19.18%
% of Gross Profit
Research & Development	$3.370M	$3.488M	$4.880M
YoY Change	-36.65%	-28.52%	-16.55%
% of Gross Profit
Depreciation & Amortization	$350.0K	$400.0K	$404.0K
YoY Change	-12.5%	-0.99%	-2.42%
% of Gross Profit
Operating Expenses	$6.030M	$5.713M	$6.648M
YoY Change	-21.79%	-14.06%	-17.3%
Operating Profit		-$5.713M	-$6.648M
YoY Change		-14.06%	-17.3%
Interest Expense	-$790.0K	$39.00K	$20.00K
YoY Change	-104.67%	95.0%	-13.04%
% of Operating Profit
Other Income/Expense, Net	$30.00K	-$282.0K	-$2.667M
YoY Change	-40.0%	-89.43%	6738.46%
Pretax Income	-$6.800M	-$6.000M	-$9.320M
YoY Change	-175.06%	-35.62%	15.35%
Income Tax
% Of Pretax Income
Net Earnings	-$6.800M	-$5.995M	-$9.315M
YoY Change	-175.06%	-35.64%	15.31%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.23
Diluted Earnings Per Share	-$17.00M	-$0.23	-$42.36M
COMMON SHARES
Basic Shares Outstanding	24.07M shares	22.55M	13.27M shares
Diluted Shares Outstanding		22.55M

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.981M	$12.62M	$37.99M
YoY Change	-74.99%	-66.78%	0.72%
Cash & Equivalents	$7.081M	$10.80M	$37.99M
Short-Term Investments	$900.0K	$1.821M
Other Short-Term Assets	$122.0K	$260.0K	$200.0K
YoY Change	79.41%	30.0%	-45.95%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$8.175M	$12.88M	$38.20M
YoY Change	-74.52%	-66.29%	0.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.723M	$2.814M	$4.263M
YoY Change	-29.46%	-33.99%	-22.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$140.0K	$140.0K	$140.0K
YoY Change	0.0%	0.0%	-88.24%
Total Long-Term Assets	$2.860M	$2.951M	$4.600M
YoY Change	-28.45%	-35.85%	-36.23%
TOTAL ASSETS
Total Short-Term Assets	$8.175M	$12.88M	$38.20M
Total Long-Term Assets	$2.860M	$2.951M	$4.600M
Total Assets	$11.04M	$15.83M	$42.80M
YoY Change	-69.41%	-63.01%	-5.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$776.0K	$827.0K	$1.665M
YoY Change	-51.13%	-50.33%	-16.79%
Accrued Expenses	$2.705M	$1.518M	$4.290M
YoY Change	28.99%	-64.62%	75.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$180.0K	$320.0K	$580.0K
YoY Change	-68.97%	-44.83%	0.0%
Total Short-Term Liabilities	$3.805M	$2.914M	$7.209M
YoY Change	-26.42%	-59.58%	7.76%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$320.0K
YoY Change	-100.0%	-100.0%	-64.84%
Other Long-Term Liabilities	$18.50M	$17.73M	$31.23M
YoY Change	7.81%	-43.23%	1941.18%
Total Long-Term Liabilities	$18.50M	$17.73M	$31.55M
YoY Change	6.69%	-43.8%	1193.03%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.805M	$2.914M	$7.209M
Total Long-Term Liabilities	$18.50M	$17.73M	$31.55M
Total Liabilities	$22.30M	$20.64M	$38.76M
YoY Change	-0.92%	-46.75%	324.76%
SHAREHOLDERS EQUITY
Retained Earnings	-$208.2M	-$201.4M	-$190.8M
YoY Change	14.53%	5.53%	21.38%
Common Stock	$196.9M	$196.6M	$194.9M
YoY Change	0.81%	0.88%	0.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.435M	-$4.813M	$4.036M
YoY Change
Total Liabilities & Shareholders Equity	$11.04M	$15.83M	$42.80M
YoY Change	-69.41%	-63.01%	-5.53%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	-$6.800M	-$5.995M	-$9.315M
YoY Change	-175.06%	-35.64%	15.31%
Depreciation, Depletion And Amortization	$350.0K	$400.0K	$404.0K
YoY Change	-12.5%	-0.99%	-2.42%
Cash From Operating Activities	-$4.320M	-$5.730M	-$5.460M
YoY Change	-26.78%	4.95%	-20.64%
INVESTING ACTIVITIES
Capital Expenditures	-$150.0K	-$50.00K	-$10.00K
YoY Change		400.0%	-98.0%
Acquisitions
YoY Change
Other Investing Activities	$900.0K	$6.160M
YoY Change
Cash From Investing Activities	$750.0K	$6.100M	-$10.00K
YoY Change		-61100.0%	-98.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-150.0K	-140.0K	27.53M
YoY Change	-21.05%	-100.51%	-23041.67%
NET CHANGE
Cash From Operating Activities	-4.320M	-5.730M	-5.460M
Cash From Investing Activities	750.0K	6.100M	-10.00K
Cash From Financing Activities	-150.0K	-140.0K	27.53M
Net Change In Cash	-3.720M	230.0K	22.06M
YoY Change	-38.92%	-98.96%	-394.13%
FREE CASH FLOW
Cash From Operating Activities	-$4.320M	-$5.730M	-$5.460M
Capital Expenditures	-$150.0K	-$50.00K	-$10.00K
Free Cash Flow	-$4.170M	-$5.680M	-$5.450M
YoY Change	-29.32%	4.22%	-14.58%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24071029	shares
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37994000
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1518000
CY2017Q3	us-gaap	Assets Current AssetsCurrent	12877000
CY2017Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	6424000
CY2017Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10563000
CY2017Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	196419000
CY2017Q3	us-gaap	Assets Assets	15828000
CY2017Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	1800000
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	827000
CY2017Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	1821000
CY2017Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	1821000
CY2017Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1821000
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10798000
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22791066	shares
CY2017Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	12600000
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22791066	shares
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	159000
CY2017Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	289000
CY2017Q3	us-gaap	Deferred Revenue Leases Current DeferredRevenueLeasesCurrent	185000
CY2017Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	60000
CY2017Q3	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	3040000
CY2017Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1700000
CY2017Q3	us-gaap	Incentive From Lessor IncentiveFromLessor	527000
CY2017Q3	us-gaap	Liabilities Liabilities	20641000
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15828000
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2914000
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	178000
CY2017Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	146000
CY2017Q3	us-gaap	Loans Payable LoansPayable	324000
CY2017Q3	us-gaap	Loans Payable Current LoansPayableCurrent	324000
CY2017Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	258000
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2814000
CY2017Q3	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	13871000
CY2017Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13377000
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	137000
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-201391000
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	120000
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.60
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	327000
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2027533	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	362000
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	934872	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.91
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2194630	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.48
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	-4813000
CY2017Q3	hsgx	Fair Value Input Amount Transfer Between Levels FairValueInputAmountTransferBetweenLevels	0
CY2017Q3	hsgx	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	2.76
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30915000
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2097000
CY2016Q4	us-gaap	Assets Current AssetsCurrent	32081000
CY2016Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	360000
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9387000
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	195181000
CY2016Q4	us-gaap	Liabilities Liabilities	22511000
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1588000
CY2016Q4	us-gaap	Assets Assets	36078000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31908000
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20647612	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20647612	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	159000
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	315000
CY2016Q4	us-gaap	Deferred Revenue Leases Current DeferredRevenueLeasesCurrent	407000
CY2016Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	136000
CY2016Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	3040000
CY2016Q4	us-gaap	Incentive From Lessor IncentiveFromLessor	610000
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36078000
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5171000
CY2016Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	178000
CY2016Q4	us-gaap	Loans Payable Current LoansPayableCurrent	583000
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	173000
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3860000
CY2016Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	13197000
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13247000
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	137000
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-181773000
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1577016	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.95
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	13567000
CY2016Q4	hsgx	Fair Value Input Amount Transfer Between Levels FairValueInputAmountTransferBetweenLevels	0
CY2016Q3	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	27600000
CY2016Q3	hsgx	Minimum Threshold Percentage Of Beneficial Common Stock Interest MinimumThresholdPercentageOfBeneficialCommonStockInterest	0.0499	pure
CY2016Q3	hsgx	Maximum Threshold Percentage Of Beneficial Common Stock Interest On Holders Discretion MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion	0.0999	pure
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1233000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-24000
	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	0
	us-gaap	Depreciation Depreciation	1267000
	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	0
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-21110000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19618000
	us-gaap	Convertible Preferred Stock Terms Of Conversion ConvertiblePreferredStockTermsOfConversion	The Series A Preferred Stock shall not be converted if, after giving effect to the conversion, the holder and its affiliated persons would own beneficially more than 4.99% of our common stock (subject to adjustment up to 9.99% solely at the holder’s discretion upon 61 days’ prior notice to us or, solely as to a holder, if such limitation is waived by such holder upon execution of the private placement agreement).
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Depreciation Depreciation	1178000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.74
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	673000
	dei	Entity Registrant Name EntityRegistrantName	Histogenics Corporation
	dei	Entity Central Index Key EntityCentralIndexKey	0001372299
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6717000
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-360000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-578000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-761000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	85000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	114000
	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <b>1. NATURE OF BUSINESS</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>Organization</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Histogenics Corporation (the “Company”) was incorporated under the laws of the Commonwealth of Massachusetts on June 28, 2000 and has its principal operations in Waltham, Massachusetts. In 2006, the Company’s board of directors approved a corporate reorganization pursuant to which the Company incorporated as a Delaware corporation. The Company is a cell therapy company engaged in developing and commercializing products in the musculoskeletal segment of the marketplace. The Company combines cell therapy and tissue engineering technologies to develop products for tissue repair and regeneration and is initially focused on patients suffering from cartilage-derived pain and immobility. The Company’s most advanced product, NeoCart<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">®</sup>, is currently in a Phase 3 clinical trial in the United States (the “U.S.”) under a special protocol assessment with the U.S. Food and Drug Administration (“FDA”) for the treatment of knee cartilage damage. In June 2017, the Company announced that it had completed enrollment in the NeoCart Phase 3 clinical trial. The Company expects to report top-line data in the third quarter of 2018 and file a Biologics License Application (“BLA”) with the FDA in the same quarter subject to successful Phase 3 clinical trial results.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> On May 13, 2011, the Company completed the acquisition of ProChon Biotech Ltd. (“ProChon”), a privately-held biotechnology company focused on modulating the fibroblast growth factor system for consideration of $2.2 million to enable it to create more effective solutions for tissue regeneration. The acquisition of ProChon provided the Company with access to a significant portfolio of intellectual property, including proprietary cell growth factors, in addition to furthering opportunities for the use of biomaterials to create more effective solutions for regenerating human tissue. The acquisition led to the initial recognition of goodwill, which was subsequently written off in 2011, and intangible assets including IPR&D and a licensing agreement which have been fully-impaired.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> On December 18, 2014, the Company formed a wholly owned subsidiary, Histogenics Securities Corporation, under the laws of the Commonwealth of Massachusetts.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> On September 29, 2016, the Company closed a private placement of common stock, preferred stock and warrants, contemplated by a securities purchase agreement dated September 15, 2016, with certain institutional and accredited investors. The net proceeds after deducting placement agent fees and other transaction-related expenses was $27.6 million. See Note 6, Capital Stock, for further discussion of the private placement.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Since its inception, the Company has devoted substantially all of its efforts to product development, recruiting management and technical staff, raising capital, starting up production and building infrastructure and has not yet generated revenues from its planned principal operations. Expenses have primarily been for research and development and related administrative costs.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company is subject to a number of risks. The developmental nature of its activities is such that significant inherent risks exist in the Company’s operations. Principal among these risks are the successful development of therapeutics, successfully enrolling patients in its clinical trials in a timely manner, ability to obtain adequate financing, obtaining regulatory approval for any of its product candidates in any jurisdiction, obtaining adequate reimbursement rates for any of its approved product candidates, compliance with government regulations, protection of proprietary therapeutics, fluctuations in operating results, dependence on key personnel and collaborative partners, adoption of the Company’s products by the physician community, rapid technological changes inherent in the markets targeted, the introduction of substitute products and competition from larger companies.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Liquidity</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements, the Company had an accumulated deficit at September 30, 2017 of $201.4 million and has incurred losses and cash flow deficits from operations for the nine months ended September 30, 2017 and 2016. The Company has financed operations to date primarily through private placements of equity securities, including the sales of common stock and preferred stock, and the related issuance of warrants in September 2016, the issuance of common stock in the initial public offering completed in December 2014, and borrowings under debt agreements. The Company anticipates that it will continue to incur net losses for the next several years and will require additional capital to complete the filing of a BLA with the FDA and commercialize NeoCart, if approved, and for the future development of its existing product candidates. However, the Company expects that total operating expenses will be lower over the next four quarters than the previous four quarters. As of September 30, 2017, the Company had approximately $12.6 million of cash and cash equivalents and marketable securities. Given the Company’s current development plans, it anticipates that its existing cash and cash equivalents and marketable securities will be not be sufficient to fund its operations beyond the middle of 2018. Accordingly, these factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">  </p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> To meet its capital needs, the Company intends to raise additional capital through debt or equity financing or other strategic transactions. However, there can be no assurance that the Company will be able to complete any such transaction on acceptable terms or otherwise. The failure of the Company to obtain sufficient funds on commercially acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition. The forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of our expenses could vary materially and adversely as a result of a number of factors. The Company has based its estimates on assumptions that may prove to be wrong, and the Company’s expenses could prove to be significantly higher than it currently anticipates.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Basis of Accounting</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The consolidated financial statements are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). However, they do not include all of the information and footnotes required by GAAP for complete financial statements. These interim consolidated financial statements, in the opinion of the Company’s management, reflect all normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the interim periods ended September 30, 2017 and 2016. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2016, and the notes thereto, which are included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on March 16, 2017.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The consolidated financial statements include the accounts of Histogenics Corporation and its wholly-owned subsidiaries, ProChon and Histogenics Securities Corporation. All significant intercompany accounts and transactions are eliminated in consolidation.</p> </div>
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1977000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-18701000
	us-gaap	Operating Expenses OperatingExpenses	18917000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-432000
	us-gaap	Net Income Loss NetIncomeLoss	-19618000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18917000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-701000
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	743000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-142000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	8004000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	132000
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6159000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5000
	us-gaap	Repayments Of Debt RepaymentsOfDebt	437000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12200000
	us-gaap	Sales Revenue Net SalesRevenueNet	0
	us-gaap	Share Based Compensation ShareBasedCompensation	1233000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M19D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.76
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0203	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y7M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	234889	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.01
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.96
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.27
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.72
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0.000	pure
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate	0.630	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.631	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y3M19D
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P6Y29D
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0128	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	860000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	7497	shares
	dei	Trading Symbol TradingSymbol	HSGX
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22219666	shares
	hsgx	Net Income Loss Available To Series A Preferred Stock NetIncomeLossAvailableToSeriesAPreferredStock	-3238000
	hsgx	Deferred Rent And Lease Incentive DeferredRentAndLeaseIncentive	407000
	hsgx	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-16380000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1080000
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	3056000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	7079000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25271000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.90
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-539000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6141000
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	1256000
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-94000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	40000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-358000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-120000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-55000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-317000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-19843000
	us-gaap	Operating Expenses OperatingExpenses	22401000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	27239000
	us-gaap	Net Income Loss NetIncomeLoss	-25271000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22401000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2870000
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	742000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-298000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	317000
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	27674000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2000
	us-gaap	Repayments Of Debt RepaymentsOfDebt	437000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16260000
	us-gaap	Sales Revenue Net SalesRevenueNet	0
	us-gaap	Share Based Compensation ShareBasedCompensation	1080000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0139	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.40
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0.000	pure
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate	0.636	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.597	pure
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P7Y0M0D
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0159	pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13279833	shares
	hsgx	Net Income Loss Available To Series A Preferred Stock NetIncomeLossAvailableToSeriesAPreferredStock	-74000
	hsgx	Deferred Rent And Lease Incentive DeferredRentAndLeaseIncentive	400000
	hsgx	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-25197000
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	435000
CY2016Q3	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	3056000
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9315000
CY2016Q3	us-gaap	Depreciation Depreciation	404000
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.70
CY2016Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-539000
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1768000
CY2016Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-20000
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	6648000
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-9315000
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6648000
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2667000
CY2016Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	248000
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-130000
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4880000
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	0
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0136	pure
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.47
CY2016Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0.000	pure
CY2016Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate	0.632	pure
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.852	pure
CY2016Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P6Y11M19D
CY2016Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0153	pure
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13297546	shares
CY2016Q3	hsgx	Net Income Loss Available To Series A Preferred Stock NetIncomeLossAvailableToSeriesAPreferredStock	-81000
CY2016Q3	hsgx	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-9234000
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	369000
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5994000
CY2017Q3	us-gaap	Depreciation Depreciation	389000
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2017Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	269000
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2225000
CY2017Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	39000
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	5713000
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-5995000
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5713000
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-282000
CY2017Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	248000
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-52000
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3488000
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	0
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0195	pure
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.14
CY2017Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0.000	pure
CY2017Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate	0.597	pure
CY2017Q3	hsgx	Net Income Loss Available To Series A Preferred Stock NetIncomeLossAvailableToSeriesAPreferredStock	-915000
CY2017Q3	hsgx	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-5080000
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.600	pure
CY2017Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P6Y29D
CY2017Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0135	pure
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22552341	shares

Files In Submission

Name	View Source	Status
0001193125-17-338756-index-headers.html	Edgar Link	pending
0001193125-17-338756-index.html	Edgar Link	pending
0001193125-17-338756.txt	Edgar Link	pending
0001193125-17-338756-xbrl.zip	Edgar Link	pending
d395446d10q.htm	Edgar Link	pending
d395446dex311.htm	Edgar Link	pending
d395446dex312.htm	Edgar Link	pending
d395446dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hsgx-20170930.xml	Edgar Link	completed
hsgx-20170930.xsd	Edgar Link	pending
hsgx-20170930_cal.xml	Edgar Link	unprocessable
hsgx-20170930_def.xml	Edgar Link	unprocessable
hsgx-20170930_lab.xml	Edgar Link	unprocessable
hsgx-20170930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OCGN
Ocugen, Inc. Stock $ocgn

2017 Q4 Form 10-Q Financial Statement

#000119312517338756 Filed on November 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OCGN Ocugen, Inc. Stock $ocgn

2017 Q4 Form 10-Q Financial Statement

#000119312517338756 Filed on November 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OCGN
Ocugen, Inc. Stock $ocgn